Ligand Pharmaceuticals Incorporated

Stock Chart, Company Information, and Scan Results

$231.78(as of Apr 20, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ligand Pharmaceuticals Incorporated Company Information, Fundamentals, and Technical Indicators

Stock Price$231.78
Ticker SymbolLGND
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees47
CountyUSA
Market Cap$4,622.8M
EBIDTA81.0M
10-Day Moving Average218.15
P/E Ratio39.37
20-Day Moving Average209.12
Forward P/E Ratio27.32
50-Day Moving Average202.56
Earnings per Share6.13
200-Day Moving Average182.19
Profit Margin75.06%
RSI67.32
Shares Outstanding19.9M
ATR10.12
52-Week High234.76
Volume110,776
52-Week Low98.89
Most Recent Support Level218.19
Book Value1,017.2M
Most Recent Resistance Level234.76
P/B Ratio4.82
Upper Keltner231.89
P/S Ratio18.28
Lower Keltner186.34
Debt-to-Equity Ratio231.89
Next Earnings Date05/13/2026
Cash Surplus137.5M
Next Ex-Dividend DateUnknown

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.

Ligand Pharmaceuticals Incorporated In Our Stock Scanner

As of Apr 21, 2026
example chart graphic
Scan Name: Doji CandlesScan Type: Candlestick Pattern Scans
As of ---
example chart graphic
Scan Name: Increasing Book ValueScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: 52-Week HighScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Long Legged DojiScan Type: Candlestick Pattern Scans
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.